GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » Asset Turnover

Clovis Oncology (Clovis Oncology) Asset Turnover : 0.08 (As of Sep. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Clovis Oncology's Revenue for the three months ended in Sep. 2022 was $30.7 Mil. Clovis Oncology's Total Assets for the quarter that ended in Sep. 2022 was $369.8 Mil. Therefore, Clovis Oncology's Asset Turnover for the quarter that ended in Sep. 2022 was 0.08.

Asset Turnover is linked to ROE % through Du Pont Formula. Clovis Oncology's annualized ROE % for the quarter that ended in Sep. 2022 was 57.04%. It is also linked to ROA % through Du Pont Formula. Clovis Oncology's annualized ROA % for the quarter that ended in Sep. 2022 was -60.59%.


Clovis Oncology Asset Turnover Historical Data

The historical data trend for Clovis Oncology's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology Asset Turnover Chart

Clovis Oncology Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.12 0.19 0.26 0.28

Clovis Oncology Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.07 0.07 0.08 0.08

Competitive Comparison of Clovis Oncology's Asset Turnover

For the Biotechnology subindustry, Clovis Oncology's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clovis Oncology's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clovis Oncology's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Clovis Oncology's Asset Turnover falls into.



Clovis Oncology Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Clovis Oncology's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=148.757/( (605.554+472.833)/ 2 )
=148.757/539.1935
=0.28

Clovis Oncology's Asset Turnover for the quarter that ended in Sep. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2022 )/( (Total Assets (Q: Jun. 2022 )+Total Assets (Q: Sep. 2022 ))/ count )
=30.663/( (392.856+346.775)/ 2 )
=30.663/369.8155
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Clovis Oncology  (OTCPK:CLVSQ) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Clovis Oncology's annulized ROE % for the quarter that ended in Sep. 2022 is

ROE %**(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-224.056/-392.7905
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-224.056 / 122.652)*(122.652 / 369.8155)*(369.8155/ -392.7905)
=Net Margin %*Asset Turnover*Equity Multiplier
=-182.68 %*0.3317*-0.9415
=ROA %*Equity Multiplier
=-60.59 %*-0.9415
=57.04 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Clovis Oncology's annulized ROA % for the quarter that ended in Sep. 2022 is

ROA %(Q: Sep. 2022 )
=Net Income/Total Assets
=-224.056/369.8155
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-224.056 / 122.652)*(122.652 / 369.8155)
=Net Margin %*Asset Turnover
=-182.68 %*0.3317
=-60.59 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Clovis Oncology Asset Turnover Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Clovis Oncology (Clovis Oncology) Business Description

Traded in Other Exchanges
N/A
Address
5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Executives
Thomas C. Harding officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read officer: See Remarks C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe officer: See remarks C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl officer: See remarks 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov director 1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair director 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy director, officer: President and CEO C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen director TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale officer: See remarks C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein director 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham director AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

Clovis Oncology (Clovis Oncology) Headlines

From GuruFocus